ADMA vs ANIP: fair value comparison
ADMA Biologics, Inc. and ANI Pharmaceuticals, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ADMA currently sits closer to the top of our discount ranking. ADMA carries the stronger quality grade. ADMA carries the stronger momentum grade.
| ADMA | ANIP | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $8.74 | $80.06 |
| 12-month range | $7.90–$19.38 | $75.22–$94.10 |
| Sector rank | #1 of 113 Healthcare | #11 of 113 Healthcare |
| Quality grade | B | C- |
| Momentum grade | A | B |
| Leverage | Low | Moderate |
| Margin trend | Expanding | — |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: ADMA fair value analysis · ANIP fair value analysis